School of Medical and Allied Sciences

Course Code: BPHT5003

Course Name: Pharmacology II

Haematinics, Coagulants and Anti-coagulants

GALGOTIAS UNIVERSITY

Disclaimer

All the content material provided here is only made for teaching purpose.

GALGOTIAS UNIVERSITY

ANAEMIA:

It is a condition in which the balance between production and destruction of RBCs is disturbed by:-

- 1. Blood Loss
- 2. Impaired red cell formation
- 3. Increased destruction of RBCs

HAEMATINICS

These are also called as anti-anaemics. They are the agents which are required for the formation of blood and are used for the treatment of Anaemics. These are mainly IRON, FOLIC ACID & VIT B_{12}

IRON

Distribution in the Body:

Total body iron in an adult is 2.5-5g. It is more in men than in women.

It is distributed into:--

Hemoglobin – 66%

Iron stores as ferritin & hemoglobin – 25%

Myoglobin - 3%

Parenchymal Iron – 6%

HAEMOGLOBIN

It is a protoparphyrin, each molecule having 4 iron containing haeme residues. It has 33% iron.

Daily Requirement:-

To make good average daily loss, requirement are:

Adult male
$$-$$
 0.5 – 1 mg Adult Female $-$ 1 – 2 Infants $-$ 60 μ g / kg Children $-$ 25 μ g / kg Pregnancy $-$ 3 – 5 mg

IRON ABSORPTION

The average daily diet contain 10-20 mg of iron. It absorption occurs all over the intestine, but magnify in the upper part.

Iron Transport

Iron is transmitted in blood in combination with a glycoprotien transferin it binds ferric iron. The total plasma content of iron is ~3 mg.

Iron Storage

Iron is stored in RE cells in liver, Spleen, bone in narrow in hepotocytes and myocytes as ferritin & haemosiderin.

Iron Excertion

Iron is tenaciosly conserved by the body daily excretion in adult male is 0.5 – 1mg mainly as exploiated g.l mucosal cell, some RBC & in bile.

In menstruating women, monthly menstrual loss may be averaged to 0.5 – 1 mg/day

Ferrous Fumerate – 200 – 400 mg is divided daily dose.

Colloidal iron – 200 – 400 mg daily

Parental Iron Therapy

It is indicated when oral iron therapy fails

- 1. Iron dextran injection: Dose 1 ml
- 2.Iron sorbitol injection: Dose 1.5 mg of iron / kg

Adverse Effect:-

- Local * Pain at site of in injection.
 - * Pigmentation of skin
 - * Sterile abscess
- Systemic * Fever, headache, joint pains, flushing, palpitation, chest pain, dyspnoea, lymph node enlargement
 - * A metallic taste in mouth lasting for few hrs.
 - * An anaphylactoid reaction resulting in vascular collapse & death.
- * Iron sorbital causes more imidiate reaction than iron dextran, should be avoided in patients with kidney disease

Uses:-

1. Iron Deficiency Anaemia :-

If is the most important indication for medicinal iron. Iron deficiency is the commonest cause of anaemia. Iron deficiency also accompanies repeated attacks of malaria & chronic inflammatory disease. The cause of iron-deficiency should be identified & treated with normal administration.

2. Megaloblastic Anamia:-

when brisk haemopoiesis is induced by Vit B12 or folate therapy,iron deficiency may be unmasked. The iron status of this patient should be evaluated & iron given accordingly.

3. AS AN ASTRINGENT:-

Ferric chloride is used in throat paint.

ACUTE IRON POISIONING:

It occurs when body is unable to excrete an excess of iron, which is deposited in heart, liver, pancreas & other organ leading to organ failure & death. It occurs mostly in infants& children. It is very rare in adults.

Manifestation are

vomiting, abdominal pain, haematemesis, diarrhoea, lethargy, cyanosis, dehydration, acidosis, convulsions & finally shock, cardiovascular collapse & death.

TREATMENT:

Prevent further absorption of iron from gut.

Induce vomiting or perform gastric lavage with sodium bicarbonate solution to render iron insoluble.

Give egg yolk & milk orally complete iron.

Maturation Factors:-

Vitamin B₁₂ & folic acid deficiency, results in megaloblastic anaemia. They are, therefore, called maturation factors

VITAMIN B₁₂

Cyanocobalamin & hydroxycobalamin are complex cobalt containing compounds in diet & refered to as vitamin B₁₂

Dietary Sources:- Liver, kidney, sea fish, egg yolk, meat, cheese are the main vitamin B₁₂ containing constituents of diet. Legumes is only vegetable source.

METABOLIC FUNCTIONS:-

Vitamin B_{12} is intricately linked with folate metabolism in many ways like megaloblastic anaemia occuring due to deficiency of either is indistinguishable.In addition vitamin B_{12} has some independent functions as well –

- 1-It is essential for the conversion of homocysteine to metionine.
- 2-Vitamin B₁₂ is essential for cell growth & multiplication.
- 3-Vitamin B_{12} is also essential for degeneration of spinal cord.

DEFICIENCY:-

- 1-Addisonian pernicious anaemia
- 2-Malabsorption bowel resection
- 3-Other causes of mucosal damage eg; Chronic gastritis, gastric carcinoma, gastrectomy
- 4-Nutritional deficiency: less common cause
- 5-Increased demand- pregnancy, infancy

USES:

- 1-Used in treatment of B₁₂ deficiency.
- 2-Mega doses of B₁₂ have been used in neuropathies, psyciatric disorders, cutaneous sarcoid & as a general folic to allay fatigue, improved growth

Adverse effects:

Even large doses of B₁₂ are quite safe. Allergic reaction have occurred on injection, probably due to contaminants. Anaphylactoid reactions have occurred on injection, this route should not be applied.

GALGOTIAS UNIVERSITY

FOLIC ACID

It occurs yellow crystals which are insoluble in water, but its sodium salt is freely soluble water.

Dietary Sources:-

Liver, green leafy vegetables, egg, meat, milk

DEFICIENCY:-

- 1-Megaloblastic anaemia
- 2-Epithelial damage
- 3-General deability, weight loss, sterility.

Metabolic Functions:-

- 1-Conversion of homoysteine into methionine
- 2-Generation of thymidylate, an important constituent of DNA
- 3-Conversion of serine into glycine
- 4-Purine synthesis
- 5-Histidine metabolism

GALGOTIAS UNIVERSITY

USES

- 1-In megaloblastic anaemia
- 2-In methotrexate toxicity
- 3-Citrovorum factor rescue
- 4-Antiepileptic therapy

ADVERSE EFFECT-

Oral folic acid is entirely nontoxic. Infection rarely causes sensitivity reaction.

Coagulant and Anti-coagulant Classes of Drugs

- Prevent coagulation
- Dissolve clot
- Prevent bleeding and hemorrhage
- Overcome clotting deficiencies

Phases of Blood Clotting


- Vascular Phase
- Platelet Phase
- Coagulation Phase
- Fibrinolytic Phase

Coagulation Phase

- > Two major pathways
 - Intrinsic pathway
 - Extrinsic pathway
- > Both converge at a common point
- > 13 soluble factors are involved in clotting
- > Normally inactive and sequentially activated

Intrinsic Pathway


Extrinsic Pathway



Vitamin K-Dependent Clotting Factors



Natural anti-coagulant



Drugs influencing coagulation

• fibrin formation ————— Anticoagulants

Platelet function
Antiplatelet drugs

• Fibrinolysis Thrombolytic drugs

Anticoagulants

Anti-thrombin activators

Direct thrombin inhibitors

Direct Factor Xa inhibitors

Drugs that oppose action of Vitamin K

<u>Heparin</u>


Heterogeneous mixture of branched glycosaminoglycans

Potentiates the inhibition of IIa, IXa, Xa, XIa, XIIa by AT

 Binds to AT through a unique pentasaccharide sequence leading to a conformational change

Intrinsic Pathway

Extrinsic Pathway



Heparin

- Given s.c. or i.v.
- Binds to plasma proteins, endothelial cells & macrophages
- Elimination
 - Depolymerisation in endothelial cells & macrophages (rapid, saturable)
 - Renal (slow, non-saturable) and RES

GALGOTIAS UNIVERSITY

Heparin: variable anticoagulant effect

- Variable protein binding
- Clearance varies with chain length

- Therefore, anticoagulant response monitored by activated partial thromboplastin time (APTT)
- Target 1.5 2.5 times control

Clinical uses of Heparin

Venous thrombosis ± embolism

Acute coronary syndromes

Arterial thrombosis

• Extracorporeal devices (e.g. haemodialysis)

Heparin: adverse effects

Bleeding

- Heparin-induced thrombocytopenia (HIT)
 - Immune-mediated
- Osteoporosis

Low-molecular-weight heparins (LMWHs)

Derived from UFH by chemical or enzymatic depolymerization

Molecular weight 2000 – 9000

About 15 monosaccharide units per molecule

Differences in Mechanism of Action

 Any size of heparin chain can inhibit the action of factor Xa by binding to antithrombin (AT)

• In contrast, in order to inactivate thrombin (IIa), the heparin molecule must be long enough to bind both antithrombin and thrombin

Less than half of the chains of LMWH are long enough

LMWHs

- Dalteparin
- Enoxaparin
- Tinzaparin

GALGOTIAS UNIVERSITY

Direct thrombin inhibitors

Recombinant hirudins


• Bivalirudin

• Ximelagatran / Melagatran

Dabigatran


Warfarin Mechanism of Action





Intrinsic Pathway

Extrinsic Pathway



Vit. K dependent Factors Affected by Oral Anticoagulants

Warfarin

- Anticoagulant effect seen after 2-3 days
- Monitored by international normalized ratio (INR)
- Well absorbed form GIT
- Highly protein bound
- Metabolised by CYP-450

Adverse effects of Warfarin

• Bleeding

Rashes

Alopecia

Teratogenicity


Antiplatelet drugs

COX inhibitors

- Adenosine diphosphate P2Y₁₂ receptor antagonists (thienopyridines)
- Phosphodiesterase inhibitors
- Glycoprotein IIb/IIIa receptor antagonists

Aspirin

Irreversible acetylation of cyclo-oxygenase-1 in platelets



Thienopyridines

- Ticlopidine
- Clopidogrel



Clopidogrel

- Slightly more effective than aspirin
- Additive effect to aspirin

Use

- MI
- Stroke

Ticlopidine

Slow onset of action: 3-7 days

Idiosyncratic neutropenia

GALGOTIAS UNIVERSITY

Antiplatelet drugs

- COX inhibitors
- Adenosine diphosphate P2Y₁₂ receptor antagonists (thienopyridines)
- Phosphodiesterase inhibitors
 - Dipyridamole
- Glycoprotein IIb/IIIa receptor antagonists

<u>Dipyridamole</u>

Phosphodiesterase inhibitor



Glycoprotein IIb/IIIa receptor antagonists

Abciximab, Eptifibatide

More complete inbibition of platlet function

inceased risk of bleeding

More complete inbibition of platlet function

inceased risk of bleeding

GALGOTIAS UNIVERSITY


Drugs influencing coagulation

Anticoagulants

Antiplatelet drugs

• Thrombolytic drugs

Fibrinolysis



<u>Fibrinolysis</u>

Exogenously administered drugs

Streptokinase

Urokinase

Tissue plasminogen activator (tPA)

Streptokinase:

Binds to plasminogen & activates it

• Source: β haemolytic streptococci

• Immunogenic (not repeated within one years of administration)

• T 1/2 - 20 min

• IV

Clinical uses

- STEMI
- Massive pulmonary embolism
- Ischaemic stroke
- Better if give within first 3 hr

Side effects

- Bleeding
- Multiple microemboli
- Cardic arrhythmias
- Allergy

Urokinase

Human fetal kdney tisssue

Activate plaminogen

•T1/2 - 15 min

<u>tPA</u>

- Produced by recombinant DNA technology
- Not immunogenic
- More clot-specific than SK fibrin selective
- Less coagulation disturbance in plasma
- Short half life iv infusion

References

- 1. Tripathi KD. 'Essentials of Medical Pharmacology', 6th edition, Jaypee Brothers Medical publications (P) Ltd., New Delhi, 2003.
- 2. Dale M M, Rang H P, and Dale M M. Rang & Dale's Pharmacology', 7th edition. Edinburgh: Churchill Livingstone, 2007.
- 3. Guyton, A. C. and Hall, J. E. 2006. Textbook of Medical Physiology. 11th Edition. Saunders, Philadelphia.

GALGOTIAS UNIVERSITY